This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nikolsky, E. Articles by Stone, G. W. Search for Related Content PubMed Articles by Nikolsky, E. Articles by Stone, G. W. Related Collections Related Article

Prognostic Impact of Blood Transfusion After Primary Angioplasty for Acute Myocardial Infarction

Analysis From the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial

Eugenia Nikolsky, MD, PhD^_*, Roxana Mehran, MD^_*, H. Mehrdad Sadeghi, MD, Cindy L. Grines, MD, David A. Cox, MD, Eulogio Garcia, MD^||, James E. Tcheng, MD^¶, John J. Griffin, MD^#, Giulio Guagliumi, MD^_**, Thomas Stuckey, MD, Mark Turco, MD, Martin Fahy, MSc^_*, Alexandra J. Lansky, MD^_*, Gregg W. Stone, MD^_*,_*

^_* Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
Sharp Chula Vista Medical Center, Chula Vista, California
William Beaumont Hospital, Royal Oak, Michigan
Mid Carolina Cardiology, Charlotte, North Carolina
^|| Hospital Gregorio Maranon, Madrid, Spain
^¶ Duke Clinical Research Institute, Durham, North Carolina
^# Virginia Beach General Hospital, Virginia Beach, Virginia
^_** Ospedali Riuniti di Bergamo, Bergamo, Italy
Moses Cone Memorial Hospital, Greensboro, North Carolina
Washington Adventist Hospital, Tacoma Park, Maryland

View larger version (14K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Histogram of In-Hospital Nadir Hematocrit Values in Patients Receiving an RBC Transfusion The mean ± standard deviation nadir hematocrit in patients who received transfusion was 29.9 ± 4.65%. In more than one-half of transfused patients (53.7%), nadir hematocrit was >30%.

View larger version (24K): [in this window] [in a new window] [Download PPT slide]   Figure 2 Kaplan-Meier Estimates of Adverse Events at 1 Year Cumulative adverse event rates during 1 year of follow-up in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction stratified by red blood cell transfusion. (A) Death; (B) reinfarction; (C) target vessel revascularization; (D) disabling stroke; and (E) composite major adverse cardiovascular events (MACE).